Innovent acquires China commercial rights to abemaciclib; Nomura maintains Buy
AI summary card
Innovent acquires China commercial rights to abemaciclib; Nomura maintains Buy
Nomura believes this mature breast cancer drug can strengthen Innovent's commercialized product portfolio and support its FY27E product sales target of CNY20bn.
- Innovent reached a partnership with Eli Lilly to obtain the commercial rights in China for abemaciclib (Verzenio).
- Global sales of abemaciclib were USD5.7bn/USD1.3bn in FY25/1Q26, up 8%/12% YoY; sales in China's sample hospitals were CNY984mn/CNY279mn, up 3%/11% YoY.
- Nomura expects Innovent may fully consolidate sales of the drug, but due to profit sharing with Eli Lilly, margins may be lower than those of its in-house drugs.
Report interpretation
Overview
This report is a company quick comment by Nomura on Innovent (1801.HK). The core event is Innovent's acquisition of the China commercial rights to Eli Lilly's CDK4/6 inhibitor abemaciclib. The report believes this transaction will deepen Innovent's marketed drug portfolio and help achieve its FY27E product sales target of CNY20bn.
Core views
Nomura holds a positive view on the event: on one hand, Eli Lilly may be more focused on new drugs such as GLP-1 RA, and thus is handing commercialization of mature products like abemaciclib, which face generic competition, to partners; on the other hand, Innovent has collaborated with Eli Lilly multiple times in the past and has strong commercialization capabilities, which is an important reason it again obtained these rights.
Analysis framework
The report mainly uses event-driven analysis, combined with abemaciclib's global and China sales performance, CDK inhibitor market share, the division of responsibilities between the two parties, Innovent's product sales targets, and the DCF valuation framework, to assess the impact of the transaction on the company's revenue and valuation.
Methodology notes
Target price calculation
Nomura's target price of HKD114.64 is based on a DCF model, discounted to the end of 2025, assuming a WACC of 10.3% and a terminal growth rate of 4.0%.
Buy
Buy indicates that the analyst expects the stock to outperform its benchmark index over the next 12 months; the benchmark index in this report is the Hang Seng Index.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Innovent（1801.HK）Directly covered name, benefiting from acquiring the China commercial rights to abemaciclib.
- Strengths
- It already has strong commercialization capabilities and a solid foundation of multiple collaborations with Eli Lilly; the addition of a mature drug helps enrich the product portfolio.
- Weaknesses
- abemaciclib is a mature drug, and its margin may be lower than that of in-house products due to partnership profit sharing.
- Comparison
- In the division of responsibilities with Eli Lilly, Innovent is responsible for importation, commercialization, and distribution, while Eli Lilly is responsible for manufacturing and supply.
- Risks
- The CDK inhibitor market may be eroded by generics, and the company still faces GLP-1 drug competition, biosimilar VBP, and uncertainty in the clinical development of IBI363.
- Eli Lilly（LLY US）Counterparty to the transaction, granting Innovent the China commercial rights to abemaciclib.
- Strengths
- Retains manufacturing and supply, and can focus more resources on new drugs such as GLP-1 RA.
- Weaknesses
- After handing the China commercial rights of a mature product to a partner, its direct control over commercialization declines.
- Comparison
- Eli Lilly provides the mature product and supply capabilities, while Innovent provides commercialization execution in the China market.
- Risks
- abemaciclib in China faces generics awaiting market entry and share erosion.
Key data
- RatingBuyRating maintained.
- Target priceHKD 114.64Target price maintained.
- Closing priceHKD 79.60Closing price on 2026-06-30.
- Implied upsideapproximately 44.0%Calculated based on the target price of HKD114.64 and the closing price of HKD79.60.
- Global sales of abemaciclibFY25 USD5.7bn；1Q26 USD1.3bnUp 8% and 12% YoY, respectively.
- Sales in China's sample hospitalsFY25 CNY984mn；1Q26 CNY279mnUp 3% and 11% YoY, respectively, corresponding to CDK inhibitor category market shares of about 41% and 37%.
- Innovent product sales targetFY27E CNY20bnThe report believes this partnership will help the company move toward this target.
- Current valuation3.0x FY35F salesCorresponding to FY35F sales of CNY41bn.
Impact & implications
This partnership will add to Innovent a mature drug that has already been approved, included in the NRDL, and has an established sales base, which is expected to increase revenue scale and improve the completeness of its commercialized product portfolio; however, since Eli Lilly remains responsible for manufacturing and supply and there is profit sharing, the drug's margin may be lower than that of Innovent's in-house drugs.
Risks
- Intensifying competition in GLP-1 drugs.
- Price and margin pressure from biosimilar VBP.
- Setbacks in the clinical development of IBI363.
- abemaciclib in China faces two generics awaiting market entry, which may erode share.
- Profit sharing on partnered drugs may result in margins below those of Innovent's in-house drugs.
What to watch
- Further financial details of the cooperation agreement between Innovent and Eli Lilly.
- Actual recognized revenue and margin performance of abemaciclib in China.
- Changes in CDK inhibitor market share and the launch progress of generics.
- Progress toward achieving Innovent's FY27E product sales target of CNY20bn.
- Clinical progress of IBI363 and the competitive landscape related to GLP-1.